Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRUST: FOLFOXIRI + Bevacizumab in Rectal Cancer
NCT03085992Phase 2Completed
- Sponsor
- Azienda Ospedaliero-Universitaria Pisana
- Start
- Mar 2012
- Primary completion
- Jul 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in rectal cancer, sponsored by Azienda Ospedaliero-Universitaria Pisana. Started Mar 2012; status: completed.
02
Drugs
bevacizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03085992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03085992.